The potency of substituted benzimidazoles such as E3810, omeprazole, RO 18-5364 to inhibit gastric H+,K+-ATPase is correlated with the rate of acid-activation of the inhibitor
- 1 February 1990
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 39 (4), 661-667
- https://doi.org/10.1016/0006-2952(90)90143-9
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- The specificity of omeprazole as an (H++K+)-ATPase inhibitor depends upon the means of its activationBiochemical Pharmacology, 1987
- Inhibition of (H+ + K+)-ATPase by omeprazole in isolated gastric vesicles requires proton transportBiochimica et Biophysica Acta (BBA) - Biomembranes, 1987
- Inhibition of gastric K+/H+-ATPase by acid-activated 2-((2-pyridylmethyl)sulphinyl) benzimidazole productsEuropean Journal of Pharmacology, 1987
- The mechanism of action of the antisecretory agent omeprazoleJournal of Medicinal Chemistry, 1986
- Histamine and duodenal ulcer: effect of omeprazole on gastric histamine in patients with duodenal ulcer.Gut, 1986
- Acid activation of (H+–K+)-ATPase inhibiting 2-(2-pyridylmethyl-sulphinyl)benzimidazoles: isolation and characterization of the thiophilic ‘active principle’ and its reactionsJournal of the Chemical Society, Chemical Communications, 1986
- Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in ratsDigestive Diseases and Sciences, 1984
- Omeprazole in Zollinger–Ellison SyndromeNew England Journal of Medicine, 1984
- Effect of substituted benzimidazoles on acid secretion in isolated and enriched guinea pig parietal cells.Gut, 1983
- Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.Gut, 1983